PsyRx

Unique solutions for depression

PsyRx is developing an innovative and unique drug to treat patients suffering from depression - one of the most common diseases in the world! The development is based on innovative and breakthrough production technology,

658% of funding target

12

Units left

₪50,000

Minimum investment

12

Days to go
To view the table of benefits in the current fundraising round, please click here
By: Prof. Itamar Grotto
Overfunding
Investment type:
Company Stage:
Category:
Digital Health

Highlights

Highlights

PsyRx Ltd developing a new drug for one of the most common diseases in the world! The development is combining an FDA-approved SSRI drug with a low dose of  ibogaine, a mind -expanding psychedelic substance found at the root of the iboga plant, that has been proven in research to affect depression.

 

Patents, cooperation, and a strong scientific team

 

PsyRx has applied for a patent application for a drug combining a low dose of Ibogaine with antidepressants. The patent has already been accepted in South Africa and the company believes that it will soon be approved in other countries. The company has a significant collaboration with the Hebrew University, for the benefit of developing production methods for rare substances in the world of pharma and has a high-quality team, led by Prof. Itamar Grotto, former Deputy Director General of the Ministry of Health and Nobel laureate in chemistry, Professor Aharon Chachanover.

 

Millions were invested in the company from a group of private investors, headed by the American NFT fund TRIPPY.VC, some of whose founders are Rowan Marley (Bob Marley's son) and NBA star, Amara Stoudemire.

 

Update 1: In a study conducted by Stanford University and published in "Nature" magazine (January 2024), it was found that Ibogaine is effective for head injuries and post-traumatic stress disorder (PTSD). The study showed that a single use resulted in an improvement of over 80% in PTSD symptoms (!) such as in depression and anxiety symptoms, the results were statistically significant and the improvement occurred in a very short response.

 

Update 2: PsyRx has successfully completed the pre-clinical safety trial of the drug combination - this is a mandatory requirement of the Ministry of Health and a significant milestone towards continued development.

 

Update 3: PsyRx has completed development of the technical manufacturing file for Ibogaine manufacturing  - putting PsyRx as one of the only companies in the world that can produce pharma-grade Ibogaine for human use. Ibogaine trading can be a significant revenue stream for PsyRx in the pharmaceutical industry.

Depression - 2030 epidemic 

The mental health crisis is a global epidemic: 1 out of 4 people will suffer from mental problems and the Corona epidemic has made the situation even worse. Tens of thousands of people die tragically each year because of dealing with mental illness. Beyond the family isolation,loneliness and social crisis, the phenomenon of depression has severe economic consequences for the economy of every country. Estimates are that by 2030 the global cost is expected to reach trillions of dollars.

 

In addition, extreme and formative events, such as the corona epidemic that broke out in 2020, may be a significant catalyst for a widespread increase in the scope of the phenomenon. We all saw a vivid example of this here in Israel, when following the events of October 7 there was a significant increase in the use of antidepressants.

 

 Yoav Elishov, PsyRx CEO at the Knesset's drug and Narcotics Committee.Aid to the victims of October 7


 

Is there a treatment for depression? According to a report published by the World Health Organization, 71% of those diagnosed with depression are not treated! The existing psychiatric drugs are not effective enough and cause serious side effects such as weight gain, decreased libido, sleeping disorders and more. These drugs have a long onset-effect time and only low to moderate effectiveness. 35%-40% of patients who suffer from major depression do not respond to the common treatments with SSRI antidepressant drugs, and patients' situations  do not improve - some do not even show a partial response. On top of that, the patients on medication experience functional impairment, poor quality of life, suicidal thoughts, self-harm, suicide attempts and unfortunately - a high relapse rate.

 

PsyRx - Nice to Treat

 

PsyRx is developing a breakthrough therapeutic concept, based on a new drug that will combine Ibogaine, a miraculous plant that has received research recognition, and an existing drug for depression already approved by the FDA. Ibogaine is a psychoactive mind-altering substance, found in the roots of the African plant Iboga. Ibogaine has been proven to be effective for the treatment of mental symptoms related to depression and post-traumatic stress disorder. Based on studies that have already been carried out around the world, it is suggested that the combination of ibogaine with existing drugs can have a positive and rapid effect within a few days of the onset of the drug's effect. This change is dramatic compared to traditional drugs, whose effect only begins later after a couple of weeks. In addition, the drugs on the market have severe side effects, which cause many patients to stop the treatment in the middle. Using an ibogaine-based drug may significantly reduce these side effects, thus allowing the patient to continue taking the drug without compromising the treatment sequence.The development of the drug is done in accordance with the guidelines of the Ministry of Health and by leading scientists and experts from the top of academia and the Pharma industry!

Simultaneously with drug solution, PsyRx has developed innovative methods for cultivation, production, extraction, and separation of psychoactive molecules, based on botanical sources such as ibogaine, derived from the Voacanga Africana plant, and psilocybin, derived from Psilocybe mushrooms.

 

PsyRx employs integrated agro-medical methods and bioreactor technology to produce substances that can be used for the development of antidepressant medication and other drugs based on consciousness expanders, currently in various stages of development in the pharmaceutical industry.

These are valuable and rare raw materials sought after by the pharmaceutical industry. Their production capacity would provide PsyRx with significant additional revenue streams alongside antidepressant drug development.

The company boasts experienced management and a high-quality scientific staff.

The founders of the company have a rich and successful experience in establishing new companies, launching products in the life sciences arena, and issuing offerings on the stock market. The company's scientific team consists of leading experts in biotechnology, drug development, and business.

 

 


 

The team

The founders of the company have vast experience in establishing new companies and commercializing new products in the life sciences arena. The company's team consists of leading experts in the fields of medicine, biotechnology, drug development and business.

Prof. Itamar Grotto, chairman of the company's board of directors, is a doctor MD, specializing in public health and a professor of epidemiology, who served at the Israeli Ministry of Health and was a member of the executive committee of the World Health Organization (WHO).

Yoav Elishoov CEO . Pharmacist ,MBA. more than 25 years in the Pharma Industry, swerve as Novartis Oncology Israel and CIS markets head, CEO of Trima ltd, and business development consultant to global and local  pharma companies .

Prof. Moshe Kotler MD , psychiatrists, is a former director of the Be'er Yaakov - Nes Ziona Mental Health hospital,

Dr. Asher Holzer, co-founder, Has over 30 years‘ experience in management of both private and public corporations in the medical device and the biotech industry.

Dr. Kobi Boxdorf has over 10 years of experience in academic, industrial and managerial research, in the fields of microbiology, plant sciences and medical devices. These experts are joined by other leading entrepreneurs and scientific and medical professionals in various fields.

PsyRx's scientific and management team provides the company with the necessary expertise to realize the company's vision of providing innovative solutions for the treatment of depression.

 

 

PsyRx Market Overview

According to recent  estimates, approximately 26% of Americans aged 18 and older suffer from a mental disorder in a given year, and around 17.3 million adults in the United States experience at least one major depressive episode in their lifetime. Additionally, about 40 million adults in the United States suffer  from anxiety disorders. This phenomenon is also widespread in the UK. According to the UK Office for National Statistics, one in every six people is affected by depression. These numbers are expected to increase due to the side effects of the global coronavirus pandemic, as reported by various organizations and institutions.

Moreover, unhealthy eating habits, demanding work schedules, increased isolation from family and loved ones against the backdrop of technological advancements, and the inability to adapt to the rapidly advancing pace of the world - all contribute to the increase in various psychiatric symptoms in general - particularly anxiety and depression.

The promising results from studies on consciousness-altering substances (psychoactive) have increased their use across the United States and in other regions, leading to a growing demand in many countries. Although the industry using these substances is still in its infancy and the companies traded in it are only at the beginning of their journey, there are very significant capital flows into the market, with hundreds of millions of dollars in investments flowing between October 2020 and January 2021.

So far, major pharmaceutical companies have not invested in psychoactive substances due to various regulatory issues. However, now, due to regulatory ease (FDA in the United States and EMEA in Europe), large pharmaceutical companies are beginning to invest, and are expected to increase their investments and incorporate psychoactive substances into their drug pipelines.

Company's Market Position:

PsyRx is the only company offering a combination of an approved SSRI family drug combined  with a psychoactive substance as a prescription medication.

The company targets the global mental health market, not just the psychedelics market.

Development of cultivation, production, extraction, and separation systems for molecules from biological sources.

Offers sale of Active Pharmaceutical Ingredients (API) + third-party sales/licensing.

PsyRx aims to become the largest player in this field due to its cutting-edge technology.

Our Technology

PsyRx's technology for producing psilocybin is based on the use of tissue cultures of the Psilocybe mushroom to generate a high and consistent yield of psilocybin production through bioreactor technology. Additionally, semi-synthetic ibogaine is produced from the Voacanga Africana plant. The development of these methods allows for significantly lower production costs compared to existing production methods today.

The quality of production under appropriate conditions and the production of psilocybin and ibogaine are prerequisites for any drug development, adding the challenge of producing these plant-derived substances. Currently, psychoactive substances of botanical origin are produced using traditional agricultural methods, which have drawbacks including concerns about contamination, pesticide use, radiation, and various active compound variations.

Today, it is almost impossible to find in the market molecules of psilocybin and ibogaine from botanical sources that are produced under appropriate manufacturing conditions required for human use. Therefore, the vast majority of current research and development in the field is based on synthetic molecules that differ in some properties from the original plant material.

Additionally, there is a demand in the market from pharmaceutical companies, mental health clinics, and research centers for an active substance from botanical sources, which is produced under appropriate conditions, high quality, and in a uniform manner.

PsyRx's developed technology allows for the production of ibogaine (as an active substance) API from the root bark of the Voacanga Africana plant and the production of psilocybin API through tissue culture cultivation.

PsyRx has developed a precise process conducted in a controlled environment, ensuring the production of molecules of high quality, maximum speed, and significantly higher efficiency compared to conventional production methods. Since the development takes place under appropriate manufacturing conditions and full compliance with GMP and stringent regulatory requirements, the company can produce a large quantity of material at relatively low economic costs. This enables PsyRx to sell the material to pharmaceutical companies, research and development facilities, or develop drugs themselves at an affordable price with high profit margins.

Unique Patents and Investments in the Company

PsyRx is on its way to achieving strong intellectual property, covering the combination of ibogaine with antidepressant drugs.

PsyRx collaborates with one of the leading patent law firms in Israel, specializing in patent registration and protection. The strong IP base is expected to provide a significant barrier against potential competitors. In 2021, the company filed its first patent for the combination of ibogaine with SSRIs for the treatment of depression. Currently, the company is conducting efficacy research in animals to strengthen the patent.

This patent has already been granted in South Africa, providing the company with a significant competitive advantage.

PsyRx's progress doesn't happen in a vacuum; the company has already raised millions of shekels from a private investor group in 3 funding rounds, opening the door for its developments, achievements, and successes.

One of the investors in the company is the American NFT fund TRIPPY.VC, whose founders include Rohan Marley (son of Bob Marley) and NBA star Amar'e Stoudemire.

 

 

Research Collaborations

The company has a collaboration agreement with the Hebrew University of Jerusalem (Faculty of Agricultural, Food and Environmental Quality Sciences), which includes:

1) Development of methods for extraction, separation, purification of botanical material and conversion into an active pharmaceutical ingredient (API) for commercial production for various uses, such as: pharmaceutical industry for drug development, clinical research, hospitals, and mental health clinics, among others.

2) Development of a method for ibogaine production.

3) Development of a bioreactor for tissue culture of Psilocybin mushrooms for commercial production of API substances at GMP level (Good Manufacturing Practice conditions).

The developments are carried out in university laboratories in full cooperation.

PsyRx has completed a preclinical safety trial and is working on a protocol for human research.

Why Ibogaine?

Not just ibogaine: Consciousness-expanding substances have been available for therapeutic and mental health treatment since ancient times. However, in the last 50 years, they have been pushed to the sidelines mainly due to various political reasons.

In recent years, there has been a significant increase in research on these substances, which consistently show their enormous potential for treating a variety of health conditions. For example, clinical trials have shown that MDMA is highly effective in treating Post-Traumatic Stress Disorder (PTSD). Ketamine (originally an anesthetic) effectively treats depression and suicidal tendencies — in Israel, the Ministry of Health approved a depression drug with ketamine components in 2020, which also entered the drug health  basket  (reimbursment)

Psilocybin is effective in treating depression and anxiety, and ibogaine is effective in treating substance addictions, alongside depression and anxiety treatment. These treatments usually involve short-term administration of high doses, which cause psychoactive effects and therefore require close integration and monitoring by professionals in a controlled clinical environment.

However, there are many indications that these substances can be used in low doses (Microdosing) that do not cause psychedelic effects, in order to alleviate psychiatric/psychological symptoms and improve the quality of life of patients.

Several studies in addiction research have demonstrated the effectiveness of ibogaine and noribogaine (a secondary metabolite of ibogaine) in reducing the search for various addictive substances such as heroin, cocaine, morphine, methamphetamine, nicotine, and alcohol. The data also indicate their effectiveness in influencing psychological symptoms related to depression and trauma. Research in this field is growing, and recently a clinical trial was approved providing ibogaine for opioid withdrawal.

In a recent study conducted by Stanford University and published in the journal "Nature Medicine ", ibogaine was found to be an effective treatment for head injury and post-traumatic stress disorder (PTSD) victims. The study was conducted on 30 American combatants suffering from PTSD and brain damage from explosions and blasts. The study showed that ibogaine use significantly reduced or completely eliminated some of the severe symptoms of PTSD, including depression, anxiety, intrusive thoughts, paranoia, hyperarousal, outbursts of anger, guilt, detachment, sleep problems, and more. The astonishing thing is that a single use of ibogaine led to an improvement of over 80% in PTSD symptoms, as well as depression and anxiety symptoms.

The results were statistically significant, and improvement occurred in a short response time of days to months.

PsyRx is one of the few companies in the world holding a technical dossier to produce ibogaine at a pharmaceutical level, meaning a drug substance suitable for human use. The company is in advanced stages towards commercialization and production of ibogaine with the intention to start marketing the substance to medical institutions and laboratories worldwide.

This production is expected to be a significant source of income for the company!

Business Model

The company's business model consists of the following elements:

1. Sales of a new antidepressant drug.
2. Signing licensing agreements for the manufacturing and marketing of psychiatric drugs. The company plans to combine existing drugs with ibogaine to enhance efficacy and reduce side effects.
3. Sales of active pharmaceutical ingredients (APIs) of psilocybin and ibogaine for research and drug development purposes.
4. Sale of technology usage rights through sublicense or tech transfer (in bioreactors) to third parties in exchange for royalties.
5. The company plans to establish joint ventures with companies developing drugs based on psilocybin and ibogaine for various indications. Initially, the company will produce API substances that will be sold to potential customers such as commercial companies and research institutions for experiments and medical developments.

Regulatory Pathway for Drug Development

PsyRx is focusing on the research and development of an innovative Combination Therapy regimen using ibogaine HCL in microdose, aimed at treating patients suffering from severe Major Depressive Disorder (MDD) who do not improve or show only partial response to existing antidepressant treatments. These treatments are mostly based on Selective Serotonin Reuptake Inhibitors (SSRIs) and therefore suffer from "treatment-resistant depression".

The company is currently establishing its intellectual property through various trials, which are required to demonstrate the safety and efficacy of the treatment and will allow it to begin the first clinical trial in humans in Israel, which will demonstrate the success of the combination treatment.

Currently, the company is working on a pre-clinical efficacy trial to demonstrate the effectiveness of the combination therapy.

Based on vital information derived from the human trial, the company will submit a Pre-IND meeting request to the U.S. Food and Drug Administration (FDA), for the purpose of further development and to assess the feasibility of conducting the required research in patients in the United States. Regulatory submission in the United States will be based on the 505(b)(1) pathway, based on the results of the initial clinical trial indicating the combined therapy's ability to address an "unmet medical need" in the treatment of a severe or life-threatening condition. Additionally, the company will seek recognition for development in a fast track designation or breakthrough therapy designation – pathways that expedite regulatory approval for drug use.

PsyRx in the media


Pitch

Pitch

The Idea

 

The problem

Mental health is in a global crisis. One out of every four people suffers from a mental problem, and thousands of people die tragically every year as a result of mental illness. The Covid-19 epidemic further increased prevalence, and the global economic consequences (e.g., loss of productivity) are estimated to reach trillions of dollars by 2030.

Depression is a common mental disease that has a significant impact on the patients' quality of life. Traditional treatments for these conditions often have long onset times and limited efficacy, as well as many side effects (e.g., weight gain, decreased libido, sleep disorders).

Many patients (about 35%-40%) who suffer from major depression do not respond adequately to common treatments with SSRI antidepressants, do not improve, or show a partial response. In addition, many patients fail to complete treatment due to the side effects of these drugs. At the same time, patients experience functional impairment, poor quality of life, suicidal thoughts and suicide attempts, self-injurious behavior, and a high relapse rate. 

 

The solution

PsyRx is developing a drug to treat depression through an innovative combination of Ibogaine with an antidepressant from the SSRI family that is already on the market.

Ibogaine is extracted from a botanical source, and its transformation into a pharma-grade API is carried out in a semi-synthetic process.

Psychedelic substances have been in use for healing and mental health care since the dawn of time. After being marginalized for political reasons for about five decades, recent years have shown a significant increase in research of these substances, which clearly and consistently show great potential for treating a variety of health conditions.

Several studies in addiction research have demonstrated the efficacy of Ibogaine and Noribogaine (a secondary metabolite of Ibogaine) to reduce self-administration or seeking of various addictive substances such as heroin, cocaine, morphine, methamphetamine, nicotine and alcohol. The data also indicate positive effects on psychological symptoms related to depression and trauma.

Recently, a clinical study providing Ibogaine for opiate withdrawal was approved in the USA.

 

 

 

The technology

PsyRx uses innovative manufacturing technology. The technology is based on the use of tissue cultures for the production of a high and consistent yield of Psilocybin (using a bioreactor), and semi-synthetic Ibogaine from the Voacanga Africana plant. The cost of this production is significantly lower compared to currently used production methods.

Production of quality Psilocybin and Ibogaine APIs and the use of proper manufacturing conditions are a prerequisite for any drug development, but extracting these from the plant is a challenge. Currently, botanical psychoactive substances are produced using traditional agricultural methods, which have disadvantages such as contamination, use of pesticides, radiation and great variability of the active compounds.

Today it is almost impossible to buy botanical-based Psilocybin and Ibogaine molecules that were produced under adequate production conditions necessary for human use. Therefore, the vast majority of current research and development in the field is based on synthetic molecules that differ in some of their properties from the botanic material.

In addition, there is a demand from pharmaceutical companies, mental health clinics, and research centers, for an active substance from botanical sources that is produced under proper conditions, with high quality and in a consistent fashion.

The technology developed by PsyRx enables the production of API Ibogaine from the root bark of the Voacanga Africana plant and the production of API Psilocybin from tissue cultures.

PsyRx's bioreactor technology offers a fast, efficient and reliable way to produce Ibogaine and Psilocybin under proper manufacturing conditions (GMP standard), through the development of a precise process in a controlled environment, which brings our products to the highest quality.

These molecules are also produced at a fast pace, which is significantly more efficient compared to current production methods. The process allows the company to produce a large amount of material at a low cost, thereby selling the material to pharmaceutical companies and research and development institutes, while at the same time developing an in-house drug, at an affordable price and with high profit margins. 

These are great news for those using, producing and developing drugs based on these molecules.

 

(bioreactors in PsyRx's labs)

Intellectual Property

PsyRx submitted a patent application in 2021 and is on track to obtain strong intellectual property covering the combination of Ibogaine and antidepressants. This strong IP base should provide a strict barrier against potential competitors.

 

Collaborations

PsyRx has signed a cooperation agreement with the Tech Transfer company "Yissum" of the Hebrew University of Jerusalem (Faculty of Agriculture in Rehovot). This agreement allows the development of a method for extracting, distilling, purifying and purifying a plant-based psychedelic molecules (Ibogaine and Psilocybin) and turning it into a GMP-level APIs for various uses: clinical studies, mental health clinics (treatment in regulated markets), etc.

 

 

The business model

The company's business model consists of the following factors:

  1. Selling an improved antidepressant.
  2. Signing licensing agreements for the production and marketing of psychiatric drugs. The company plans to combine existing drugs with Ibogaine to increase effectiveness and reduce side effects.
  3. Sale of API Psilocybin and Ibogaine for research and drug development.
  4. Sublicense or transfer of technology usage rights to a third party in exchange for royalties.
  5. Establishment of joint ventures with companies developing drugs based on Psilocybin and Ibogaine for various indications.

In the first stage, the company will produce raw material which will be sold to potential customers such as commercial companies and research institutions, for the purpose of experiments and medical developments.

 

 

PsyRx in the media 

Team

Team

Prof. Itamar Grotto
chairman of the board
Biography
Public Health Physician and Professor of Epidemiology. Prof. Grotto served as the Director of Public Health Services (2007-2017) at the Israeli Ministry of Health, later to become the Associate Director General (2017-2021). Between 2018 and 2021 he was a Member of the Executive Board of the World Health organization (WHO).

  • Key Employee
  • Chairman of the Board
Yoav Elishov
CEO
Biography
Has over 25 years of experience in the pharmaceutical industry. Yoav served as CEO of Tarima Pharmaceuticals Ltd. between 2013 and 2018. Between 2001 and 2012, Yoav founded and managed Novartis Oncology in Israel and then expanded its activities to the developing countries of Eastern Europe. During last year‘s Yoav was an advisor to pharma companies, medical cannabis and medical startup companies. Holds a master‘s degree in business administration MBA from Bar Ilan University and a bachelor‘s degree in pharmacy from the Hebrew University, school of pharmacy, Jerusalem.

  • Key Employee
Dr. Asher Holzer
co-founder
Biography
Has over 30 years‘ experience in management of both private and public corporations in the medical device and the biotech industry. His expertise covers a wide range of activities including product development, clinical studies, regulatory affairs and marketing. Asher founded several successful biotech companies and served as their chairman and president. These included InspireMD (NYSE MKT: NSPR), a medical device company which improves treatment of patients undergoing heart stenting and UroGen Pharma (NASDAQ: URGN) focusing on developing therapies for urological pathologies. Asher was part of the management team of Biosense which was acquired by Johnson & Johnson in 1997 and became the worldwide market leader in developing and marketing products for the diagnosis and treatment of cardiac arrhythmias. He holds a Ph.D. in Applied Physics and a M.Sc. in Material Science from Hebrew University in Jerusalem, Israel. He holds several granted and pending patents, mainly in the fields of interventional cardiology and urology.

  • Founder
  • Partner
Itay Hecht
Biz Dev & Co-Founder
Biography
Entrepreneur with experience in the private and public sector. He initiated the first IPO of a medical cannabis company on the Tel Aviv Stock Exchange. He served as the CEO of Hi-Pharma a medical cannabis company and COO of Palgi Sharon - Israeli Municipal Water Corporation. He holds a degree in Water & Soil Engineering from the Ruppin Academic Center, and a B.A. in Geography and Environment from Haifa University, Israel.

  • Founder
  • Partner
Prof. Moshe Kotler
MD , PhD
Biography
Doctor of Medicine, the Hebrew University and Hadassah Hospital in Jerusalem. 1985 completed his residency in psychiatry at the Shalvata Mental Health Center (Hod Hasharon) affiliated to Tel Aviv University. Kotler was one of the founders of the military mental health department , in the years 1985-1989 served as its head (at the rank of lieutenant colonel in the reserves). Research fellow in biological psychiatry and psychopharmacology at the Albert Einstein School of Medicine of Yeshiva University in New York for two years. 1991, director of the psychiatric department at Beth Israel Hospital in Newark, New Jersey. 1993, returned to Israel and was appointed director of the system at Ben-Gurion University of the Negev, and in 2000, deputy dean for teaching at the faculty. At the same time, he graduated with a master‘s degree in health systems management.

  • Key Employee
  • Advisor
Dr. Kobi Buxdorf
CTO & Co-Founder
Biography
Founder of Cannadorf. He has over 10 years of academic, industrial research and management experience, in the fields of microbiology, molecular biology, plant sciences, diagnostics, and medical devices. He also has extensive background in regulation, business development and commercialization of science-based products. Kobi holds a B.Sc. in Horticulture and Plant Protection (Summa Cum Laude), M.Sc. in plant genetics and breeding (Summa Cum Laude) both from The Hebrew University of Jerusalem, an M.A. in Business Administration from the College of Management, and a Ph.D. from the Hebrew University of Jerusalem.

  • Founder
  • Partner
Dr. Liron Gal
COO
Biography
Fermentation and tech. transfer expert, with over 10 years of industry and academic experience. Liron served in pharmaceutical companies in different positions, bringing to the table vast experiments in management and research. Her expertise are drug developing, protein fermentation & purification, biology assays, and manufacturing. She also holds QC and QA knowledge and a Ph.D. in Molecular Biology from the Weizmann institute of science.

  • Key Employee
Prof. Maggie Levy
Head of Agricultural Research
Biography
Since 2006, Maggie is the head of a laboratory in the Department of Plant Pathology and Microbiology at the Hebrew University of Jerusalem. The research activities in Maggie‘s laboratory combine basic and applied research focusing on plant-pathogen interactions and plant immunity. She is also an expert in plant secondary metabolites and studies their effect on fungal pathogens. So far, Prof. Maggie Levy has won highly competitive research grants and published an impressive number of articles in leading professional journals.

  • Key Employee
Dr. Noam Ygael
Research Officer
Biography
Has over 15 years of academic experience in the field of neuroscience and over 10 years of industrial experience at a medical device company (BrainsWay) that targets psychiatric conditions. He planned and managed both preclinical and clinical experiments and has vast experience in the a priori scientific literature reviews, in analyzing and interpreting results, and in their communication to different audiences. Noam holds a B. Tech in Biotechnology Engineering from the Ort Braude College, an M.Sc. in Life Sciences from the Bar-Ilan University (in cooperation with the Weizmann institute), and a Ph.D. from the Ben-Gurion University.

  • Key Employee
Dr. Jonathan Baram
Scientist
Biography
A senior researcher within the chemical industry with over 8 years of industry experience. Prior to PsyRX, Jonathan served as a senior phytochemist in Synergio, organic chemistry researcher in Chemada Fine Chemicals and formulation chemist in S.A.N advanced protection systems, where he led several point-of-care product developments from bench to market. He holds a Ph.D. in Organic chemistry from the Weizmann institute of science.

  • Key Employee
Prof. Aaron Ciechanover
Biography
Prof. Aaron Ciechanover (MD, D.Sc) - Member of the Scientific Advisory Board Nobel laureate in chemistry, member of the Faculty of Medicine at the Technion, member of the Israeli National Academy of Sciences and Humanities, and the National Academies of Sciences and Medicine of the USA. Aharon received M. Sc. and MD from the Hebrew University, and D.Sc. from the Faculty of Medicine at the Technion. With the discovery of the ubiquitin-proteasome pathway, the system became a platform. Broad for drug development, especially for malignant diseases and recently also for degenerative disorders.

  • Advisor

Financial data

Financial data

Updates 2

Updates 2

  • Update date: 14/04/2024

    PasyRx proudly announces the successful completion of two major research and development projects: 1. Safety Trial: In the combination drug, we are pleased to report the successful completion of a safety pre -clinical trial involving a combination of an antidepressant from the SSRI (Selective Serotonin Reuptake Inhibitor) along with a low dose of ibogaine. This trial assessed the safety profile of the drug combination. The next step involves conducting human trials in Israel.
  • Update date: 14/04/2024

    2. Ibogaine Production Technical file: We are excited to announce the successful completion of the technical file for ibogaine (ibogaine HCl) manufacturing . The subsequent phase involves transitioning to Good Manufacturing Practice (GMP) facilities. Planned production will enable human trials and, eventually, commercial use of ibogaine in accordance with medical standards, clinical research, and drug development. Ibogaine, a unique psychoactive substance, has been studied extensively. Notably, it was tested on 30 American combat veterans suffering from PTSD and brain injuries due to blasts and explosions. The results were remarkable: a single treatment with ibogaine significantly reduced or alleviated severe PTSD symptoms, including depression, avoidance, irritability, hyperarousal, anger outbursts, guilt, detachment, and sleep disturbances. PasyRx stands out globally as one of the few companies equipped with a technical file for pharmaceutical grade ibogaine production. This milestone positions us for commercialization and production of ibogaine under suitable manufacturing conditions. Additionally, we are actively promoting the use of ibogaine in Israel for the benefit of veterans affected by PTSD from the October 7th conflict.Best Regards
Time benefit
Investment From day 1 Until day 55 an addition of 10.00% of the the shares value
Amount benefit
Investment from an amount of 35,000 and up to an amount of 59,999 an addition of 3.00% of the the shares value
Investment from an amount of 60,000 and up to an amount of 99,999 an addition of 5.00% of the the shares value
Investment from an amount of 100,000 and up to an amount of 149,999 an addition of 6.00% of the the shares value
Investment from an amount of 150,000 and up to an amount of 1,000,000 an addition of 7.00% of the the shares value

Example A

  • Investment of ₪40,000
  • On day 1 of the campaign
an addition of of the the shares value

Example B

  • Investment of ₪100,000
  • On day 28 of the campaign
an addition of of the the shares value

Example C

  • Investment of ₪160,000
  • On day 55 of the campaign
an addition of of the the shares value
An investor who makes an investment of ₪40,000 On day 1 of the campaign ill be entitled to additional shares at a rate of aaaaa of the amount of shares that would have been issued to said investor had he not been entitled to any benefit
An investor who makes an investment of ₪100,000 On day 28 of the campaign ill be entitled to additional shares at a rate of of the amount of shares that would have been issued to said investor had he not been entitled to any benefit
An investor who makes an investment of ₪160,000 On day 55 of the campaign ill be entitled to additional shares at a rate of of the amount of shares that would have been issued to said investor had he not been entitled to any benefit
The financing rounds, made through the ExitValley platform, are in accordance with a model of statutory exemption from publishing a prospectus pursuant to sections 15A(A)(1) and 15A(A)(7) of the Israeli Securities Law - 1968.
Under this model, the disclosure of detailed information on the company and information about the investment in each round of financing are limited to not more than 35 investors, who are not qualified investors, and the round of financing is not in the format of an offering arrangement ("רכז הצעה"), as defined in the Securities Law.
Follow us